CA2179396C - Tetrahydrofuran antifungals - Google Patents

Tetrahydrofuran antifungals Download PDF

Info

Publication number
CA2179396C
CA2179396C CA002179396A CA2179396A CA2179396C CA 2179396 C CA2179396 C CA 2179396C CA 002179396 A CA002179396 A CA 002179396A CA 2179396 A CA2179396 A CA 2179396A CA 2179396 C CA2179396 C CA 2179396C
Authority
CA
Canada
Prior art keywords
compound
esters
formula
pharmaceutically acceptable
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002179396A
Other languages
English (en)
French (fr)
Other versions
CA2179396A1 (en
Inventor
Anil K. Saksena
Viyyoor M. Girijavallabhan
Raymond G. Lovey
Russell E. Pike
Haiyan Wang
Yi-Tsung Liu
Ashit K. Ganguly
Frank Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22622452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2179396(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2179396A1 publication Critical patent/CA2179396A1/en
Application granted granted Critical
Publication of CA2179396C publication Critical patent/CA2179396C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Lubricants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002179396A 1993-12-21 1994-12-20 Tetrahydrofuran antifungals Expired - Lifetime CA2179396C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17108393A 1993-12-21 1993-12-21
US08/171,083 1993-12-21
PCT/US1994/014236 WO1995017407A1 (en) 1993-12-21 1994-12-20 Tetrahydrofuran antifungals

Publications (2)

Publication Number Publication Date
CA2179396A1 CA2179396A1 (en) 1995-06-29
CA2179396C true CA2179396C (en) 2001-04-17

Family

ID=22622452

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002179396A Expired - Lifetime CA2179396C (en) 1993-12-21 1994-12-20 Tetrahydrofuran antifungals

Country Status (28)

Country Link
EP (1) EP0736030B1 (enExample)
JP (1) JP2834889B2 (enExample)
KR (1) KR0179990B1 (enExample)
CN (1) CN1064685C (enExample)
AT (1) ATE204875T1 (enExample)
AU (1) AU681753B2 (enExample)
BR (1) BR1100154B1 (enExample)
CA (1) CA2179396C (enExample)
CO (1) CO4520281A1 (enExample)
CZ (1) CZ294823B6 (enExample)
DE (2) DE69428125T2 (enExample)
DK (1) DK0736030T3 (enExample)
ES (1) ES2159623T3 (enExample)
FI (1) FI118470B (enExample)
FR (1) FR06C0009I2 (enExample)
HU (1) HU225062B1 (enExample)
IL (1) IL112081A (enExample)
LU (1) LU91216I2 (enExample)
MY (1) MY130217A (enExample)
NL (1) NL300219I2 (enExample)
NO (2) NO316173B1 (enExample)
NZ (1) NZ278713A (enExample)
PL (1) PL181193B1 (enExample)
PT (1) PT736030E (enExample)
SK (1) SK283035B6 (enExample)
TW (1) TW377349B (enExample)
WO (1) WO1995017407A1 (enExample)
ZA (1) ZA9410142B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100352147B1 (ko) * 1994-01-24 2002-11-11 얀센 파마슈티카 엔.브이. 수용성아졸항진균제
WO1996038443A1 (en) * 1995-06-02 1996-12-05 Schering Corporation Tetrahydrofuran antifungals
JPH11507668A (ja) * 1995-06-19 1999-07-06 シェーリング コーポレイション テトラヒドロフラン抗真菌剤
US5698557A (en) * 1995-06-19 1997-12-16 Schering Corporation Hydroxy-substituted antifungals
WO1997022579A1 (en) * 1995-12-20 1997-06-26 Schering Corporation Process for preparation of hydrazides
CA2255663C (en) 1996-05-24 2002-08-20 Schering Corporation Antifungal composition with enhanced bioavailability
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
ES2224256T3 (es) * 1996-06-28 2005-03-01 Schering Corporation Disolucion solida de un agente antifungico con biodisponibilidad mejorada.
HUP9903869A3 (en) * 1996-06-28 2000-07-28 Schering Corp Oral composition comprising a triazole antifungal compound
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0938487A2 (en) * 1996-11-12 1999-09-01 Sepracor, Inc. 2$i(R),4$i(S),$i(R),$i(S)- AND 2$i(S),4$i(R),$i(R),$i(S)-HYDROXYITRACONAZOLE- AND HYDROXYSAPERCONAZOLE DERIVATIVES
WO1998021205A1 (en) * 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,r,r- and 2s,4r,r,r-hydroxyitraconazole
EP0942907A1 (en) * 1996-11-12 1999-09-22 Sepracor, Inc. 2r, 4s, s, r- and 2s, 4r, s, r-hydroxyitraconazole
EP0937071A1 (en) 1996-11-12 1999-08-25 Sepracor, Inc. 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
US5684197A (en) * 1996-12-12 1997-11-04 Schering Corporation Process for preparation of hydrazides
RU2197489C2 (ru) 1997-02-11 2003-01-27 Жансен Фармасетика Н.В. Сложные эфиры аминокислот, способы их получения, промежуточные продукты, фармацевтическая композиция и способ ее получения
KR20010024297A (ko) * 1997-09-25 2001-03-26 둘락 노먼 씨. 상응하는 항진균제에 대한 프로드럭으로서의테트라하이드로푸란 포스페이트- 및 하이드록시 에스테르
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
AR015947A1 (es) * 1997-10-07 2001-05-30 Schering Corp Una forma 1 polimorfica (-)-4-[4-[4-[4-[[(2r-cis]-5-(2,4-difluorfenil)tetrahidro-5-(1h-1,2,4-triazol-1-ilmetil)furan-3-il]-metoxi]fenil]-1-piperazinil]fenil-2,4-dihidro-2-[(s)-1-etil-2-(s)-hidroxipropil]-3h-1,2,4-triazol-3-ona, composicion farmaceutica que la contiene y su uso para preparar un medic
WO1999018111A1 (en) * 1997-10-07 1999-04-15 Schering Corporation Crystalline antifungal glycine ester polymorph
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
PL351749A1 (en) 1999-05-04 2003-06-16 Janssen Pharmaceutica Nv Antifungal ethers
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
NZ528363A (en) 2001-04-03 2005-04-29 Schering Corp Liquid suspensions of posaconazole ( SCH 56592 ) with enhanced bioavailability for treating fungal infections
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7078526B2 (en) 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ITMI20032020A1 (it) 2003-10-17 2005-04-18 Italfarmaco Spa Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici
JP4792032B2 (ja) * 2004-08-13 2011-10-12 シェーリング−プラウ・リミテッド 抗生物質、トリアゾールおよびコルチコステロイドを含む薬学的処方物
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
EP2130540A1 (en) * 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
CA2767489A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
WO2011158248A2 (en) * 2010-05-12 2011-12-22 Glenmark Generics Limited Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole
CA2798010C (en) * 2010-05-19 2018-09-25 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
RU2588570C2 (ru) * 2010-05-19 2016-07-10 Сандоз Аг Способ получения хиральных гидразидов
US9073904B2 (en) 2010-05-19 2015-07-07 Sandoz Ag Preparation of posaconazole intermediates
JP6013326B2 (ja) * 2010-05-19 2016-10-25 サンド・アクチエンゲゼルシヤフト キラルトリアゾロンの調製のための方法
CN107049935A (zh) 2010-06-29 2017-08-18 默沙东公司 取代β‑环糊精稳定的泊沙康唑静脉输注液制剂
CN108329303A (zh) * 2011-06-16 2018-07-27 桑多斯股份公司 制备手性化合物的方法
EP2789610A1 (en) 2013-04-10 2014-10-15 Sandoz Ag Purification of Posaconazole Intermediates
US9670188B2 (en) 2013-07-25 2017-06-06 Sandoz Ag Process for the preparation of crystalline form IV of posaconazole
ITMI20132114A1 (it) 2013-12-18 2015-06-19 Djada Pharmaceutical Sa Una forma cristallina di posaconazolo
CN105287403A (zh) * 2014-08-02 2016-02-03 陕西合成药业股份有限公司 一种泊沙康唑前体药物的冻干组合物及其制备方法和用途
CN104370894A (zh) * 2014-10-21 2015-02-25 江苏恒盛药业有限公司 无定型泊沙康唑的制备工艺
KR102579848B1 (ko) 2014-12-05 2023-09-18 풀모사이드 리미티드 항진균 화합물
WO2016185225A1 (en) * 2015-05-21 2016-11-24 Pulmocide Limited Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.
CN106317032A (zh) * 2015-06-15 2017-01-11 重庆圣华曦药业股份有限公司 一种制备高纯度的泊沙康唑的方法
CN106432338A (zh) * 2015-08-08 2017-02-22 陕西合成药业股份有限公司 泊沙康唑衍生物、合成和在长效制剂中的用途
BR112018005934A2 (pt) * 2015-09-23 2018-10-09 Biocon Ltd formas cristalinas de intermediário de posaconazol e processo para a preparação de posaconazol amorfo
CN105606736A (zh) * 2016-01-27 2016-05-25 重庆华邦制药有限公司 分离测定泊沙康唑中间体z1及其有关物质的方法
ES2893793T3 (es) * 2016-03-04 2022-02-10 Zhejiang Ausun Pharmaceutical Co Ltd Posaconazol, composición, producto intermedio, método de preparación para el mismo y usos del mismo
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
EP3558304A2 (en) 2016-12-23 2019-10-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CN106967054A (zh) * 2017-03-30 2017-07-21 成都绿林科技有限公司 一种泊沙康唑的制备方法
CN106883221A (zh) * 2017-04-17 2017-06-23 兰州大学 一种无定形泊沙康唑及其制备方法
CN108341754A (zh) * 2018-03-12 2018-07-31 扬子江药业集团有限公司 泊沙康唑杂质及其制备方法和用途
CN110938093B (zh) * 2018-09-21 2022-08-19 华创合成制药股份有限公司 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途
CN112778369B (zh) * 2019-11-05 2024-01-26 华创合成制药股份有限公司 一种三唑类衍生物及其制备方法和用途
CN113666915B (zh) * 2021-08-27 2022-08-16 江苏海洋大学 一种泊沙康唑中间体的制备方法
CN114315811B (zh) * 2021-11-19 2024-04-30 江苏恒盛药业有限公司 一种三氮唑类似物化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
WO1989004829A1 (en) * 1987-11-20 1989-06-01 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals

Also Published As

Publication number Publication date
MY130217A (en) 2007-06-29
FI962577A0 (fi) 1996-06-20
KR0179990B1 (en) 1999-03-20
HUT75879A (en) 1997-05-28
DK0736030T3 (da) 2001-10-29
ZA9410142B (en) 1996-05-02
FI962577L (fi) 1996-06-20
EP0736030A1 (en) 1996-10-09
HU225062B1 (en) 2006-05-29
NL300219I1 (nl) 2006-04-03
TW377349B (en) 1999-12-21
EP0736030B1 (en) 2001-08-29
DE69428125T2 (de) 2002-05-02
SK82696A3 (en) 1997-03-05
NL300219I2 (nl) 2006-05-01
CZ180596A3 (en) 1997-01-15
JP2834889B2 (ja) 1998-12-14
HK1008820A1 (en) 1999-05-21
WO1995017407A1 (en) 1995-06-29
CZ294823B6 (cs) 2005-03-16
SK283035B6 (sk) 2003-02-04
NO2006002I1 (no) 2006-02-20
DE69428125D1 (de) 2001-10-04
HU9601709D0 (en) 1996-08-28
NO2006002I2 (no) 2011-03-07
NO962616L (no) 1996-08-07
ES2159623T3 (es) 2001-10-16
FI118470B (fi) 2007-11-30
JPH09500658A (ja) 1997-01-21
NO962616D0 (no) 1996-06-20
ATE204875T1 (de) 2001-09-15
FR06C0009I1 (enExample) 2006-05-19
CA2179396A1 (en) 1995-06-29
AU681753B2 (en) 1997-09-04
PT736030E (pt) 2002-01-30
BR1100154B1 (pt) 2013-11-26
CN1142828A (zh) 1997-02-12
DE122006000004I1 (de) 2006-04-27
CN1064685C (zh) 2001-04-18
IL112081A (en) 2001-08-26
LU91216I2 (en) 2006-03-27
PL181193B1 (pl) 2001-06-29
NZ278713A (en) 1997-12-19
DE122006000004I2 (de) 2007-03-29
PL315169A1 (en) 1996-10-14
FR06C0009I2 (enExample) 2006-12-29
NO316173B1 (no) 2003-12-22
AU1512795A (en) 1995-07-10
IL112081A0 (en) 1995-03-15
CO4520281A1 (es) 1997-10-15

Similar Documents

Publication Publication Date Title
CA2179396C (en) Tetrahydrofuran antifungals
EP0773941B1 (en) Tetrahydrofuran antifungals
US5661151A (en) Tetrahydrofuran antifungals
AU665218B2 (en) Trisubstituted tetrahydrofuran antifungals
US5693626A (en) Tetrahydrofuran antifungals
US5714490A (en) Tetrahydrofuran antifungals
US5703079A (en) Tetrahydrofuran antifungals
US5710154A (en) Tetrahydrofuran antifungals
US5703236A (en) Tetrahydrofuran antifungals
WO1997000248A1 (en) Hydroxyalkyl-substituted triazolones antifungals
US5698557A (en) Hydroxy-substituted antifungals
HK1008820B (en) Tetrahydrofuran antifungals
HK1008821B (en) Tetrahydrofuran antifungals
AU2778500A (en) Tetrahydrofuran antifungals
JPH10231296A (ja) テトラヒドロフラン抗真菌剤
KR19980073433A (ko) 테트라하이드로푸란 항진균제

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141222